IP Library Granted Patent US 7,683,176
Granted Patent B2
US 7,683,176 · App. 11/775,601 · Granted Mar 23, 2010

Triazolyl pyridyl benzenesulfonamides

Assignee: ChemoCentryx, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,683,176
App. No.
11/775,601
Granted
Mar 23, 2010
Kind
B2
Abstract

Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.

Claims (71)

1. A compound of the formula (I), or a salt thereof:

wherein

Ar is selected from the group consisting of substituted or unsubstituted C 6-10 aryl;

Y 1 is —CR 3a ;

Y 2 is —CR 3b ;

Y 3 is —CR 3b ;

Y 4 is —N;

R 3a , R 3b , and R 3c are each independently selected from the group consisting of hydrogen, halogen, —CN, —C(O)R 4 , —CO 2 R 4 , —C(O)NR 4 R 5 , —OR 4 , —OC(O)R 4 , —OC(O)NR 4 R 5 , —SR 4 , —S(O)R 4 , —S(O) 2 R 4 , —S(O) 2 NR 4 R 5 , —NO 2 , —NR 4 R 5 , —NR 4 C(O)R 5 , —NR 4 C(O)OR 5 , —NR 4 S(O) 2 R 5 , —NR 4 C(O)NR 5 R 6 , substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted C 2-8 alkenyl, substituted or unsubstituted C 2-8 alkynyl, and substituted or unsubstituted C 6-10 aryl;

R 4 , R 5 , and R 6 are each independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted C 2-8 alkenyl, substituted or unsubstituted C 2-8 alkynyl, and substituted or unsubstituted C 6-10 aryl;

R 1 is an unsubstituted isoxazolyl or an isoxazolyl substituted with 1 or 2 substituents independently selected from the group consisting of halogen, —CN, —CO 2 R′, —C(O)R′, —C(O)NR′R″, —OR′, —OC(O)R′, —OC(O)NR′R″, —NO 2 , —NR′C(O)R″, —NR″′C(O)NR′R″, —NR′R″, —NR′CO 2 R″, —NR′S(O)R″, —NR′S(O) 2 R″′, —NR″′S(O)NR′R″, —NR″′S(O) 2 NR′R″, —SR′, —S(O)R′, —S(O) 2 R′, —S(O) 2 NR′R″, —NR′—C(NHR″)═NR″′, —SiR′R″R″′, —N 3 , and unsubstituted C 6-10 aryl;

R 2 is selected from the group consisting of hydrogen, halogen, —CN, —C(O)R 7 , —CO 2 R 7 , —C(O)NR 7 R 8 , —OR 7 , —OC(O)R 7 , —OC(O)NR 7 R 8 , —SR 7 , —S(O)R 7 , —S(O) 2 R 7 , —S(O) 2 NR 7 R 8 , —NO 2 , —NR 7 R 8 , —NR 7 C(O)R 8 , —NR 7 C(O)OR 8 , —NR 7 S(O) 2 R 8 , —NR 7 C(O)NR 8 R 9 , substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted C 2-8 alkenyl, substituted or unsubstituted C 2-8 alkynyl, and substituted or unsubstituted C 6-10 aryl; and

R 7 , R 8 , and R 9 are each independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted C 2-8 alkenyl, substituted or unsubstituted C 2-8 alkynyl, and substituted or unsubstituted C 6-10 aryl;

wherein said substituted C 1-8 alkyl, substituted C 2-8 alkenyl, and substituted C 2-8 alkynyl have 1 to (2m′=1) substituents, where the substituents are independently selected from the group consisting of halogen, —CN, —CO 2 R′, —C(O)R′, —C(O)NR′R″, —OR′, —OC(O)R′, —OC(O)NR′R″, —NO 2 , —NR′C(O)R″, —NR″′C(O)NR′R″, —NR′R″, —NR′CO 2 R″, —NR′S(O)R″, —NR′S(O) 2 R″′, —NR″′S(O)NR′R″, —NR″′S(O) 2 NR′R″, —SR′, —S(O)R′, —S(O) 2 R′, —S(O) 2 NR′R″, —NR′—C(NHR″)═NR″′, —SiR′R″R″′, —N 3 , and unsubstituted C 6-10 aryl;

wherein m′ is the total number of carbons in said substituted alkyl, substituted alkenyl, and substituted alkynyl;

wherein said substituted C 6-10 aryl have 1 to 5 substituents independently selected from the group consisting of halogen, —CN, —CO 2 R′, —C(O)R′, —C(O)NR′R″, oxo(=O or —O − ), —OR′, —OC(O)R′, —OC(O)NR′R″, —NO 2 , —NR′C(O)R″, —NR″′C(O)NR′R″, —NR′R″, —NR′CO 2 R″, —NR′S(O)R″, —NR′S(O) 2 R″′, —NR″′S(O)NR′R″, —NR″′S(O) 2 NR′R″, —SR′, —S(O)R′, —S(O) 2 R′, —S(O) 2 NR′R″, —NR′—C(NHR″)═NR″′, —SiR′R″R″′, —N 3 , and unsubstituted C 6-10 aryl; and

wherein R′, R″and R″′ are each independently selected from the group consisting of: hydrogen, unsubstituted C 1-8 alkyl, unsubstituted C 2-8 alkenyl, unsubstituted C 2-8 alkynyl, and unsubstituted C 6-10 aryl.

2. A compound which is represented by formula (II) or a salt thereof:

wherein

Ar is selected from the group consisting of substituted or unsubstituted C 6-10 aryl;

Y 5 , Y 6 and Y 7 are each independently selected from the group consisting of hydrogen, halogen, —CN, —C(O)R 15 , —CO 2 R 15 , —C(O)NR 15 R 16 , —OR 15 , —OC(O)R 15 , —OC(O)NR 15 R 16 , —SR 15 , —S(O)R 15 , —S(O) 2 R 15 , —S(O) 2 NR 15 R 16 , —NO 2 , —NR 15 R 16 , —NR 15 C(O)R 16 , —NR 15 C(O)OR 16 , —NR 15 S(O) 2 R 16 , —NR 15 C(O)NR 16 R 17 , substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted C 2-8 alkenyl, substituted or unsubstituted C 2-8 alkynyl, and substituted or unsubstituted C 6-10 aryl; and

R 15 , R 16 and R 17 are each independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted C 2-8 alkenyl, substituted or unsubstituted C 2-8 alkynyl, and substituted or unsubstituted C 6-10 aryl R 1 is an unsubstituted isoxazolyl or an isoxazolyl substituted with 1 or 2 substituents independently selected from the group consisting of halogen, —CN, —CO 2 R′, —C(O)R′, —C(O)NR′R″, —OR′, —OC(O)R′, —OC(O)NR′R″, —NO 2 , —NR′C(O)R″, —NR″′C(O)NR′R″, —NR′R″, —NR′CO 2 R″, —NR′S(O)R″, —NR′S(O) 2 R″′, —NR″′S(O)NR′R″, —NR″′S(O) 2 NR′R″, —SR′, —S(O)R′, —S(O) 2 R′, —S(O) 2 NR′R″, —NR′—C(NHR″)═NR″′, —SiR′R″R″′, —N 3 , and unsubstituted C 6-10 aryl; R 2 is selected from the group consisting of hydrogen, halogen, —CN, —C(O)R 7 , —CO 2 R 7 , —C(O)NR 7 R 8 , —OR 7 , —OC(O)R 7 , —OC(O)NR 7 R 8 , —SR 7 , —S(O)R 7 , —S(O) 2 R 7 , —S(O) 2 NR 7 R 8 , —NO 2 , —NR 7 R 8 , —NR 7 C(O)R 8 , —NR 7 C(O)OR 8 , —NR 7 S(O) 2 R 8 , —NR 7 C(O)NR 8 R 9 , substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted C 2-8 alkenyl, substituted or unsubstituted C 2-8 alkynyl, and substituted or unsubstituted C 6-10 aryl;

wherein said substituted C 1-8 alkyl, substituted C 2-8 alkenyl, and substituted C 2-8 alkynyl have 1 to (2m′=1) substituents, where the substituents are independently selected from the group consisting of halogen, —CN, —CO 2 R′, —C(O)R′, —C(O)NR′R″, —OR′, —OC(O)R′, —OC(O)NR′R″, —NO 2 , —NR′C(O)R″, —NR″′C(O)NR′R″, —NR′R″, —NR′CO 2 R″, —NR′S(O)R″, —NR′S(O) 2 R″′, —NR″′S(O)NR′R″, —NR″′S(O) 2 NR′R″, —SR′, —S(O)R′, —S(O) 2 R′, —S(O) 2 NR′R″, —NR′—C(NHR″)═NR″′, —SiR′R″R″′, —N 3 , and unsubstituted C 6-10 aryl;

wherein m′ is the total number of carbons in said substituted alkyl, substituted alkenyl, and substituted alkynyl;

wherein said substituted C 6-10 aryl have 1 to 5 substituents independently selected from the group consisting of halogen, —CN, —CO 2 R′, —C(O)R′, —C(O)NR′R″, oxo(=O or —O − ), —OR′, —OC(O)R′, —OC(O)NR′R″, —NO 2 , —NR′C(O)R″, —NR″′C(O)NR′R″, —NR′R″, —NR′CO 2 R″, —NR′S(O)R″, —NR′S(O) 2 R″′, —NR″′S(O)NR′R″, —NR″′S(O) 2 NR′R″, —SR′, —S(O)R′, —S(O) 2 R′, —S(O) 2 NR′R″, —NR′—C(NHR″)═NR″′, —SiR′R″R″′, —N 3 , and unsubstituted C 6-10 aryl; and

wherein R′, R″ and R″′ are each independently selected from the group consisting of: hydrogen, unsubstituted C 1-8 alkyl, unsubstituted C 2-8 alkenyl, unsubstituted C 2-8 alkynyl, and unsubstituted C 6-10 aryl.

3. The compound of claim 2 , which is represented by formula (III) or a salt thereof:

wherein

X 1 , X 2 , X 3 , X 4 , and X 5 are each independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted C 2-8 alkenyl, substituted or unsubstituted C 2-8 alkynyl, —CN, —NO 2 , —C(O)R 18 , —CO 2 R 18 , —C(O)NR 18 R 19 , —OR 18 , —OC(O)R 19 , —OC(O)NR 18 R 19 , —NO 2 , —NR 18 C(O)R 19 , —NR 18 C(O)NR 19 R 20 , —NR 18 R 19 , —NR 18 CO 2 R 19 , —NR 18 S(O) 2 R 19 , —SR 18 , —S(O)R 18 , —S(O) 2 R 18 , —S(O) 2 NR 18 R 19 , and substituted or unsubstituted C 6-10 aryl; and

R 18 , R 19 and R 20 are each independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted C 2-8 alkenyl, substituted or unsubstituted C 2-8 alkynyl, and substituted or unsubstituted C 6-10 aryl.

4. The compound of claim 3 , which is represented by formula (IV), or a salt thereof:

wherein X 1 and X 2 are each independently from the group consisting of halogen, substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted C 2-8 alkenyl, substituted or unsubstituted C 2-8 alkynyl, —CN, —CO 2 R 18 , —OR 18 , —OC(O)R 19 , —OC(O)NR 18 R 19 , —NR 18 C(O)R 19 , —NR 18 C(O)NR 19 R 20 , —NR 18 R 19 , —NR 18 CO 2 R 19 , —NR 18 S(O) 2 R 19 , —NO 2 , and —SR 18 ;

Y 6 is selected from the group consisting of halogen, —CN, —OR 18 , and substituted or unsubstituted C 1-8 alkyl;

R 2 is selected from the group consisting of hydrogen, halogen, —CN, —C(O)R 7 , —CO 2 R 7 , —C(O)NR 7 R 8 , —OR 7 , —OC(O)R 7 , —OC(O)NR 7 R 8 , —SR 7 , —S(O)R 7 , —S(O) 2 R 7 , —S(O) 2 NR 7 R 8 , —NO 2 , —NR 7 R 8 , —NR 7 C(O)R 8 , —NR 7 C(O)OR 8 , —NR 7 S(O) 2 R 8 , —NR 7 C(O)NR 8 R 9 , substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted C 2-8 alkenyl, substituted or unsubstituted C 2-8 alkynyl, and substituted or unsubstituted C 6-10 aryl;

R 7 , R 8 , and R 9 are each independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted C 2-8 alkenyl, substituted or unsubstituted C 2-8 alkynyl, and substituted or unsubstituted C 6-10 aryl; and

R 18 , R 19 and R 20 are each independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted C 2-8 alkenyl, substituted or unsubstituted C 2-8 alkynyl, and substituted or unsubstituted C 6-10 aryl.

5. The compound of claim 3 , which is represented by formula (V), or a salt thereof:

6. The compound of claim 5 wherein Y 6 is selected from the group consisting of halogen and methyl.

7. The compound of claim 5 wherein X 1 and X 2 are independently selected from the group consisting of hydrogen, halogen, substituted and unsubstituted C 1 -C 4 alkyl, and OR 18 .

8. The compound of claim 7 wherein X 1 is Cl and X 2 is CF 3 .

9. The compound of claim 2 which is represented by formula (VIII), or a salt thereof:

10. The compound of claim 9 which is represented by formula (IX), or a salt thereof:

R 3 and R 4 together with the carbon which they substitute form a unsubstituted or substituted isoxazolyl.

11. The compound of claim 10 wherein R 2 is hydrogen.

12. The compound of claim 3 which is represented by formula (XI), or a salt thereof:

wherein X 1 and X 2 are each independently from the group consisting of halogen, substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted C 2-8 alkenyl, substituted or unsubstituted C 2-8 alkynyl, —CN, —CO 2 R 18 , —OR 18 , —OC(O)R 19 , —OC(O)NR 18 R 19 , —NR 18 C(O)R 19 , —NR 18 C(O)NR 19 R 20 , —NR 18 R 19 , —NR 18 CO 2 R 19 , —NR 18 S(O) 2 R 19 , —NO 2 , and —SR 18 ;

Y 6 is selected from the group consisting of halogen, —CN, —OR 18 , and substituted or unsubstituted C 1-8 alkyl;

E is O;

R 10 and R 11 are each independently selected from the group consisting of hydrogen, halogen, and substituted or unsubstituted C 1-8 alkyl;

R 2 is selected from the group consisting of hydrogen, halogen, —CN, —C(O)R 7 , —CO 2 R 7 , —C(O)NR 7 R 8 , —OR 7 , —OC(O)R 7 , —OC(O)NR 7 R 8 , —SR 7 , —S(O)R 7 , —S(O) 2 R 7 , —S(O) 2 NR 7 R 8 , —NO 2 , —NR 7 R 8 , —NR 7 C(O)R 8 , —NR 7 C(O)OR 8 , —NR 7 S(O) 2 R 8 , —NR 7 C(O)NR 8 R 9 , substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted C 2-8 alkenyl, substituted or unsubstituted C 2-8 alkynyl, and substituted or unsubstituted C 6-10 aryl;

R 7 , R 8 , and R 9 are each independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted C 2-8 alkenyl, substituted or unsubstituted C 2-8 alkynyl, and substituted or unsubstituted C 6-10 aryl; and

R 18 , R 19 and R 20 are each independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted C 2-8 alkenyl, substituted or unsubstituted C 2-8 alkynyl, and substituted or unsubstituted C 6-10 aryl.

13. The compound of claim 11 which is represented by formula (IX), or salts thereof wherein R 2 is hydrogen.

14. A compound selected from the following:

ethyl 5-(5-chloro-3-(4-chloro-3-(trifluoromethyl) phenylsulfonamido)pyridin-2-yl)-4-(isoxazol-3-yl)-4H-1,2,4-triazole-3-carboxylate;

5-(3-(4-chloro-3-(trifluoromethyl)phenylsulfonamido)-5-methylpyridin-2-yl)-4-(isoxazol-3-yl)-4H-1,2,4-triazole-3-carboxamide;

5-(5-chloro-3-(3,4-dichlorophenylsulfonamido)pyridin-2-yl)-4-(isoxazol-3-yl)-4H-1,2,4-triazole-3-carboxamide;

5-(5-chloro-3-(4-chloro-3-(trifluoromethyl)phenylsulfonamido) pyridin-2-yl)-4-(isoxazol-3-yl)-4H-1,2,4-triazole-3-carboxamide;

5-(5-chloro-3-(4-chloro-3-(trifluoromethyl)phenylsulfonamido) pyridin-2-yl)-4-(isoxazol-3-yl)-N,N-dimethyl-4H-1,2,4-triazole-3-carboxamide;

5-(5-chloro-3-(4-chloro-3-(trifluoromethyl) phenylsulfonamido) pyridin-2-yl)-N-ethyl-4-(isoxazol-3-yl)-4H-1,2,4-triazole-3-carboxamide;

5-(5-chloro-3-(4-chloro-3-(trifluoromethyl) phenylsulfonamido) pyridin-2-yl)-N-ethyl-4-(isoxazol-3-yl)-N-methyl-4H-1,2,4-triazole-3-carboxamide;

5-(5-chloro-3-(4-chloro-3-(trifluoromethyl) phenylsulfonamido) pyridin-2-yl)-N-isopropyl-4-(isoxazol-3-yl)-4H-1,2,4-triazole-3-carboxamide;

5-(5-chloro-3-(4-methyl-3-(trifluoromethyl) phenylsulfonamido) pyridin-2-yl)-4-(isoxazol-3-yl)-4H-1,2,4-triazole-3-carboxamide;

3,4-dichloro-N-(5-chloro-2-(4-(isoxazol-3-yl)-4H-1,2,4-triazol-3-yl)pyridin-3-yl)benzenesulfonamide;

4-chloro-N-(5-chloro-2-(4-(isoxazol-3-yl)-5-(methoxymethyl)-4H-1,2,4-triazol-3-yl)pyridin-3-yl)-3-(trifluoromethyl)benzenesulfonamide;

4-chloro-N-(5-chloro-2-(5-(hydroxymethyl)-4-(isoxazol-3 -yl)-4H-1,2,4-triazol-3-yl)pyridin-3-yl)-3-(trifluoromethyl)benzenesulfonamide;

N-(2-(5-bromo-4-(isoxazol-3-yl)-4H-1,2,4-triazol-3-yl)-5-chloropyridin-3-yl)-4-chloro-3-(trifluoromethyl)benzenesulfonamide; and

N-(5-bromo-2-(4-(isoxazol-3-yl)-4H-1,2,4-triazol-3-yl)pyridin-3-yl)-4-chloro-3-(trifluoromethyl)benzenesulfonamide; or a salt thereof.

15. A compound that is 5-(3-(4-chloro-3-(trifluoromethyl)phenylsulfonamido)-5-methylpyridin-2-yl)-4-(isoxazol-3-yl)-4H-1,2,4-triazole-3-carboxamide, or a salt thereof.

16. A compound that is 5-(3-(4-chloro-3-(trifluoromethyl) phenylsulfonamido)-5-methylpyridin-2-yl)-4-(isoxazol-3-yl)-4H-1,2,4-triazole-3-carboxamide.

17. A compound that is 5-(5-chloro-3-(4-chloro-3-(trifluoromethyl)phenylsulfonamido)pyridin-2-yl)-4-(isoxazol-3-yl)-4H-1,2,4-triazole-3-carboxamide, or a salt thereof.

18. A compound that is 5-(5-chloro-3-(4-chloro-3-(trifluoromethyl)phenylsulfonamido)pyridin-2-yl)-4-(isoxazol-3-yl)-4H-1,2,4-triazole-3-carboxamide.

Assignments (2)
ASSIGNEE CHANGE OF ADDRESS Recorded Jun 27, 2023
From: CHEMOCENTRYX, INC.
To: CHEMOCENTRYX, INC.
Reel/Frame 064144/0685 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2007
From: CHARVAT, TREVOR T.; HU, CHENG; JIN, JEFF; LI, YANDONG; MELIKIAN, ANITA; PENNELL, ANDREW M.K.; PUNNA, SREENIVAS; UNGASHE, SOLOMON; ZENG, YIBIN
To: CHEMOCENTRYX, INC.
Reel/Frame 020040/0137 →
Continuity (3)
Provisional Application 6083104200 · Jul 14, 2006
Provisional Application 6094585400 · Jun 22, 2007
Related Publication 20080039504A1 · Feb 14, 2008